Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412061 · ClinicalTrials.gov registry record · Phase 3
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 429
- Enrollment target
NCT00412061: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00412061 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 429 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00412061, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 429 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
Primary Outcome
Progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause. The primary analysis of PFS was based on the independent central adjudicated assessment using Kaplan-Meier method.
Interventions
- DRUG Placebo
- DRUG Everolimus
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 429 participants |
| Start Date | 2006-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT00412061 record still lists
NCT00412061 is an interventional study that assigns participants to a tested intervention. The registered 429 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00412061 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00412061 about?
NCT00412061 is a clinical study titled "Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor". The purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
What is the current status of trial NCT00412061?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 429 participants. The study started on 2006-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00412061?
The interventions under investigation include: Placebo (DRUG), Everolimus (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT00412061?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00412061's enrollment target sits among peer trials
429 878th of 2000 higher than 1,123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05932862 · 429 participants · Phase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia